Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities

Conclusions: In conclusion, halobetasol propionate 0.01% lotion provides statistically significant efficacy following 8 weeks’ therapy compared with vehicle in subjects where the leg was identified as the target lesion, with clinically relevant improvements in QoL and more than a third of subjects achieving a clinically meaningful result. J Drugs Dermatol. 2019;18(10):1029-1036. PMID: 31584782 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31584782?dopt=Abstract

Source: Journal of Drugs in Dermatology - October 5, 2019 Category: Dermatology Tags: J Drugs Dermatol Source Type: research